The presence of alkaline phosphatase (ALP, EC 3.1.3.1) bound to immunoglobulins has been frequently observed in human sera (1) (2) (3) (4) (5) (6) . IgG was the most common immunoglobulin in these complexes, 1gM being found in only one case (6) ; the ALP isoenzyme species were exclusively liver ALP (ALP-L) and bone ALP (ALP-B) (1) (2) (3) (4) . After electrophoresis and staining for the enzyme activity, these complexes showed a mobility different from that of an isoenzyme alone (1) (2) (3) (4) (5) (6) . Analyses of these complexes revealed that the immunoglobulins bind to ALP by antigen-antibody reaction through the Fab portion (7) . Usually, the immunoglobulins bound to ALP seemed to be noninhibitory antibodies to ALP (1) (2) (3) (4) Recently, by electrophoresis and gel filtration, we found a macromolecular ALP (ALP-M) in the serum of a patient. In analyzing ALP isoenzymes, we found that IgG from the patient's serum inhibited placental ALP (ALP-P) but that the ALP-M in the patient's serum consisted of IgG and intestinal ALP (ALP-I). Our findings are reported here.
Case Report
A 41-year-old Japanese man was diagnosed as having myasthenia gravis (adult type II)complicated with thymoma. Except for a slight increase in ALP activity (88 U/L, normal range 11.2 to 70 UIL), biochemical findings for his serum were within normal ranges. Electrophoretic patterns of isoen.zymes of lactate dehydrogenase, y-glutamyltransferase, leucine aminopeptidase, and amylase were all normal. Immunoglobulin contents (IgG, IgA, and 1gM) were 11.5, 2.7, and 0.8 g/L, respectively. Antibodies to the following substances were present: acetyicholine receptor, cross-striated muscle, smooth muscle, DNA, nucleoprotein, thyroglobulin, and thyroid microsomes. Immune complex was not detected by the Clq solid-phase method (8) . The percentage distributions of T and B lymphocytes were 84 and 11%, respectively, without showing abnormality, but Fe receptorbearing T lymphocytes were found to be decreased to 2. All of these data were obtained before thymectomy. Co., St. Louis, MO 63178). The nonabsorbed fraction was concentrated and tested to determine whether the fraction retained the activity to form any complex with ALP-P or ALP-I.
Materials and Methods

Preparation
Immunoprecipitation
by antisera against ALP. Immunoprecipitation of the ALP-M (prepared as described above) with antisera (E. Merck AG) against ALP-P, ALP-I, and ALP-L was performed by incubationin polyethylene glycol 6000 (3 g/L) and NaCl (150 mmol/L) for 1 h at room temperature and then for 16 h at 4 #{176}C. The mixture was then centrifuged and the ALP activity in the supernate was measured.
Formation of ALP complex. 
Results
Macromolecular Alkaline Phosphatase
Staining for the enzyme activity after electrophoresis of the patient's serum revealed two dense bands with alkaline phosphatase activity ( Figure  1 , no. 1): one for a band attributable to ALP-L and the other for an unusual ALP with slow mobility. On gel filtration of the patient's serum through Sephacryl S-300, two peaks with ALP activity were separated (data not shown). One peak coincided with normal ALP (Mr 160 000) ; the other had a higher Mr, about 900 000. On electrophoresis, normal ALP moved to the position of ALP-L, while the ALP having the higher Mr (ALPM) moved to the same position as a band with slow mobility in the patient's serum. Therefore, we believed that the unusual band seen in the patient's serum on electrophoresis was the macromolecular ALP.
Immunoglobulins Bound to ALP
The effect of the patient's serum on electrophoretic mobility of the purified ALP isoenzymes was studied to determine whether any substances that may bind to ALP, resulting in formation of macromolecular ALP, are present in free form in the patient's serum. We found that the electrophoretic mobility of ALP-L was unchanged (Figure 1 band corresponding to free ALP-P disappeared by addition of the patient's serum and a new band appeared at the origin, with significant loss of activity, whereas a band corresponding to free ALP-I remained, although decreased, and a band corresponding to ALP with slow mobility as seen in the patient's serum seemed to be increased. From these results we concluded that the patient's serum contained some free substances capable of binding to ALP-P and ALP-I, and that the complex with ALP-I was similar to the ALP-M observed in the patient's serum.
Because the presence of immunoglobulins binding to ALP and forming macromolecular species has been reported (1-6), we studied the possible involvement of immunoglobulins. As shown in Figure 2 , a band of ALP with slow mobility in the patient's serum was precipitated by antisera against human IgG, IgA, and kappa-and lambda-type light chains, but not by antiserum against human 1gM. The results of these experiments suggested that the patient's serum contained free immunoglobulins, which could bind both ALP-P and ALP-I and inhibit ALP-P activity profoundly, and that the binding of these immunoglobulins might explain, if not all points, at least the formation of the ALP-M found in the patient's serum shown in Figure 1 . Therefore, we purified IgG from the patient's serum.
As shown in Figure 3 , the purified IgG from the patient's serum strongly inhibited the ALP-P activity. Under the experimental conditions, 50% of the activity was inhibited by 0.1-0.2 g of IgG per liter, a concentration about 1% of that in the patient's serum. At these concentrations, neither ALP-L nor ALP-I activities were inhibited.
Some inhibition of ALP-I was observed when the patient's IgG was more than 2 g/L, and 20% of the activity was inhibited at an IgG Original enzyme activities as in Fig. 1. 1%, respectively.
ALP activity in the ALP-M was inhibited 74% by L-phenylalanine (5 mmol/L) and 59% by L-leucine but hardly at all (2%) by L-homoarglnine.
The heat stability of ALP-I, the ALP-M prepared above, and the complex of ALP-I with the patient's IgG was examined ( Table 1 ). The ALP-I was quite labile, as is well known (11) , but 70% of the ALP activity in the ALP-M remained.
In contrast, the complex of ALP-I with the patient's IgG was fairly stable to this treatment, although it was less stable than the ALP-M from the patient's serum. These results, taken together with results in Figures 1 (no. 7) and 4 (bottom), strongly suggested that the isoenzyme species of the ALP-M in the patient's serum was ALP-I. Figure 4 shows the formation of complexes of ALP-P or ALP-I with the patient's IgG on electrophoresis. We observed formation of the ALP-P-IgG complex at 54 mg of IgG per liter, but with an increasing amount of IgG the complex remained at the origin with significant loss of activity. In contrast, the ALP-I-IgG complex was formed with 1.73 g of the patient's IgG per liter and the complex with IgG at 6.93 g/L was quite similar to the ALP-M in the patient's serum (Figure 1, no. 1 ) and the complex of ALP-I with the patient's serum (Figure 1, no. 7 ).
After absorption of the patient's
IgG by Sepharose 4B coupled with ALP-P, we observed no formation of the complex with either ALP-P or ALP-I (data not shown), suggesting that the binding activity in the patient's IgG, not only to ALP-P but also to ALP-I, was absorbed. 
Discussion
In this paper, we describe the presence of an unusual ALP isoenzyme, Mr 900 000, in the patient's serum. Substances binding to the ALP-M were shown by immunoelectrophoresis at least to include, if not consist exclusively of IgG and
IgA. Immunoglobulin classes so far reported to bind to ALP have been primarily IgG (1) (2) (3) (4) (5) (6) , with only one case of 1gM (6) .
Although our report is the first one demonstrating the presence of IgA bound to ALP, the presence of IgA linked to amylase (12) , lactate dehydrogenase (12) , or creatine kinase (13) and a case of amylase bound to two kinds of immunoglobulins (IgG and IgA) (14) have been described.
The results shown in Figures 3 and 4 suggest that the patient's IgG was specific inhibitory antibody to ALP-P. The complex formation of ALP-I with the patient's IgG might be the result of cross reaction with antibody to ALP-P, because formation of the complex of ALP-I with the patient's IgG required more than 10-fold the IgG that complexed with ALP-P and was not observed after absorption of the patient's IgG through the affinity chromatography of Sepharose 4B coupled with ALP-P. Precipitation of the ALP activity in the ALP-M by antisera against either ALP-P or ALP-I might also be due to the cross reaction. It is generally believed (11) that the antibody to ALP-P cross reacts with ALP-I. Sussman et al. (15) , however, found the cross reaction to be due to the heterogeneity of antigen used. If ALP-P used in our experiment is contaminated with ALP-I, we can not exclude the possibility that different kinds of IgG were present in the patient's serum.
A trial to dissociate ALP from the ALP-M for analyses of ALP isoenzyme species constituting the ALP-M was hampered by the fact that ALP would not be separated from IgG by gel filtration, the Mr of both proteins being similar, when dissociated, and by the fact that the use of ion-exchange chromatography or affinity chromatography under conditions that would dissociate the antigen-antibody complex was impractical.
We did, however, conclude, from analyses of the complex formed with ALP and the patient's IgG in vitro, that the isoenzyme species constituting the ALP-M was ALP-I. We disregarded the possibility that ALP-P is an isoenzyme constituting the ALP-M in the patient's serum, because the concentration of the IgG in the patient's serum was enough to cause the almost complete inhibition of the ALP-P activity; moreover, the immune complex of ALP-P with the IgG, if it was present, remained at the origin on electrophoresis.
On the other hand, it is probable that the isoenzyme constituting the ALP-M is ALP-I. When incubated with either the patient's serum or the patient's IgG, ALP-I moved to a position with slow mobility similar to that found in the patient's serum as shown on electrophoresis. Although much greater concentrations of the patient's IgG were required to obtain the above phenomena, as compared with the similar treatment of ALP-P, the concentration of IgG in the patient's serum was sufficient to account for these phenomena.
After heat treatment at 65 #{176}C for 10 mm, 70% of the ALP activity was active in the ALP-M from the patient's serum. This is characteristic of neither ALP-P nor ALP-I, the former being completely stable and the latter labile under these conditions. Because we do not believe that ALP-P is involved in the ALP-M, as discussed above, we suggest that the ALP-I is stabilized somewhat by complexing with the IgG, as has been described for creatine kinase (16) . Although the reconstituted complex of ALP-I with the IgG was heat stable in comparison with ALP-I alone, we failed to show complete reproduction of heat stability, which was observed in the ALP-M from the patient's serum. The possible requirement of IgA or any other substances to form a heat-stable complex with ALP-I remains to be studied. Whether ALP-P, which could be an antigen for this IgG, was present in the patient's serum, is not known, because only one-half as much IgG as was in the serum almost completely inhibited the ALP-P activity, as shown in Figure  3 . It is possible that ALP-P was presentin the patient's serum. An ALP similar to ALP-P was reportly synthesized in certain cancertissues and reactedwith antibodyto ALP-P (17, 18). This possibility isunlikely, however, in thatno malignant tumors have been demonstrated in our case. Another possibility isthatthymoma itself produces ALP-P. Our preliminary cytochemical experiments demonstrated no heat-stable ALP-P activity in the resected thymoma tissue; however, the presence of an ALP-P-like antigen in the thymoma cell is possible.
